Vertex Pharmaceuticals (VRTX) Advances While Market Declines: Some Information for Investors

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $502.55, marking a +0.45% move from the previous day. The stock's change was more than the S&P 500's daily loss of 0.33%. At the same time, the Dow lost 0.37%, and the tech-heavy Nasdaq lost 0.53%.Heading into today, shares of the drugmaker had gained 4.42% over the past month, outpacing the Medical sector's loss of 3.24% and the S&P 500's loss of 4.03% in that time.The investment community will be closely monitoring the performance of Vertex Pharmaceuticals in its forthcoming earnings report. It is anticipated that the company will report an EPS of $4.19, marking a 11.97% fall compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $2.81 billion, up 4.56% from the year-ago period.In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $17.66 per share and a revenue of $11.85 billion, indicating changes of +4104.76% and +7.57%, respectively, from the former year.Any recent changes to analyst estimates for Vertex Pharmaceuticals should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, there's been a 0.1% fall in the Zacks Consensus EPS estimate. At present, Vertex Pharmaceuticals boasts a Zacks Rank of #3 (Hold).Valuation is also important, so investors should note that Vertex Pharmaceuticals has a Forward P/E ratio of 28.34 right now. For comparison, its industry has an average Forward P/E of 18.63, which means Vertex Pharmaceuticals is trading at a premium to the group.It's also important to note that VRTX currently trades at a PEG ratio of 1.22. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.52 as of yesterday's close.The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 69, which puts it in the top 28% of all 250+ industries.The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.To follow VRTX in the coming trading sessions, be sure to utilize Zacks.com.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks